Is Survival with Conservative Breast Therapy becoming Superior to that with Modified Radical Mastectomy alone for the Treatment of Early Breast Cancer in this Era?

2020 ◽  
Vol 106 (1_suppl) ◽  
pp. 24-24
Author(s):  
Mona M Sayed

Purpose: This study aims to assess survival rates in early breast cancer patients treated by Conservative breast therapy (CBT), including radiotherapy, compared to those treated by modified radical mastectomy (MRM) alone. Methods: The South Egypt Cancer Institute and the Assiut University Oncology Department patients’ records, from January 2010 to December 2017, were searched for T1-2N0-1M0 breast cancer patients treated by CBT or MRM. Patients who didn’t receive chemotherapy were excluded to reduce the treatment variation. Results: The five-year locoregional disease free survival (LRDFS) was 97.3% for the CBT patients was and 98.0% for the MRM patients (P=.675). The five-year distant disease free survival (DDFS) was 93.6% for CBS and 85.7% for MRM (P=0.033). The DFS was 91.9% for the BCT patients and 85.3% for the MRM patients (P=0.045). The five-year OS was 98.2% for the CBT patients and 94.3% for the MRM patients, (P=0.02). By Cox regression analysis, the CBT resulted in significantly better OS, (p=0.018) and the (HR=0.350, 95% CI 0.146-0.837). The adjusted OS, estimated by the propensity-score based weights, remained superior in CBT than in MRM patients (p < 0.001). Conclusion: CBT resulted in better DDFS, DFS and OS than MRM. Future randomized trials are needed to confirm these findings and determine the cause.

2011 ◽  
Vol 12 (11) ◽  
pp. 1535-1543 ◽  
Author(s):  
Ann M Moyer ◽  
Vera J Suman ◽  
Richard M Weinshilboum ◽  
Rajeswari Avula ◽  
John L Black ◽  
...  

2020 ◽  
Vol 33 (4) ◽  
pp. 137-144
Author(s):  
Guillermo Peralta-Castillo ◽  
Antonio Maffuz-Aziz ◽  
Mariana Sierra-Murguía ◽  
Sergio Rodriguez-Cuevas

Cancers ◽  
2018 ◽  
Vol 10 (12) ◽  
pp. 511 ◽  
Author(s):  
Viktor Hlavac ◽  
Maria Kovacova ◽  
Katerina Elsnerova ◽  
Veronika Brynychova ◽  
Renata Kozevnikovova ◽  
...  

The aim of our study was to set up a panel for targeted sequencing of chemoresistance genes and the main transcription factors driving their expression and to evaluate their predictive and prognostic value in breast cancer patients. Coding and regulatory regions of 509 genes, selected from PharmGKB and Phenopedia, were sequenced using massive parallel sequencing in blood DNA from 105 breast cancer patients in the testing phase. In total, 18,245 variants were identified of which 2565 were novel variants (without rs number in dbSNP build 150) in the testing phase. Variants with major allele frequency over 0.05 were further prioritized for validation phase based on a newly developed decision tree. Using emerging in silico tools and pharmacogenomic databases for functional predictions and associations with response to cytotoxic therapy or disease-free survival of patients, 55 putative variants were identified and used for validation in 805 patients with clinical follow up using KASPTM technology. In conclusion, associations of rs2227291, rs2293194, and rs4376673 (located in ATP7A, KCNAB1, and DFFB genes, respectively) with response to neoadjuvant cytotoxic therapy and rs1801160 in DPYD with disease-free survival of patients treated with cytotoxic drugs were validated and should be further functionally characterized.


Sign in / Sign up

Export Citation Format

Share Document